A recent study found that a proprietary aqueous extract of cucumber called Q-Actin, helped improve symptoms of moderate osteoarthritis in a dose-dependent manner.
A recent study1 found that a proprietary aqueous extract of Curcumis sativa (Cucumber) called Q-Actin, helped improve symptoms of moderate osteoarthritis in a dose-dependent manner. In the study, 91 patients with knee osteoarthritis were given either placebo, 20 mg of Q-Actin, and 100 mg of Q-Actin per day for 180 days. Researchers used the modified Western Ontario McMaster Universities Oste-oarthritis Index (WOMAC), the Visual Analog Scale (VAS), and the Lequesne’s Algo-Functional Index (LFI) to measure osteoarthritis parameters at 30-day intervals (30, 60, 90, 120, and 180 days).
Results showed that WOMAC score values were significantly different for subjects taking Q-Actin compared to those taking placebo. Subjects taking 20 mg of the extract experienced a 32% improvement in WOMAC scores, compared to placebo and those taking 100 mg saw a 39% improvement. Similarly, both Q-Actin groups saw significantly greater improvements in both the VAS scores and LFI scores, compared to placebo. Subjects taking 20 mg of Q-Actin experienced a 39% and 40% change in VAS and LFI scores, respectively, while those taking 100 mg saw a 45% and 50% change in VAS and LFI scores, respectively. While both doses were effective, the differences between the two Q-Actin groups indicate a dose-dependent response.
Q-Actin is marketed by IminoTech Inc. (Carson City, NV) and standardized to 1.1% idoBR1 iminosugar.
Reference
Rousselot to showcase new collagen peptide research and targeted solutions at Vitafoods Europe 2024
April 25th 2024The company will be highlighting new research that demonstrates the ability of its Peptan collagen peptide brand to support sleep quality, reduce gastrointestinal discomfort, and enhance skin health, including density, hydration, and elasticity.